EUVIMEDEUVIMED entdecken
Leitlinie

Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians

Amir Qaseem iD, Thomas G Cooney, Itziar Etxeandia-Ikobaltzeta iD, Timothy J Wilt, Curtis S Harrod, Jeffrey A Tice iD, Carolyn J Crandall, Clinical Guidelines Committee of the American College of Physicians, Lauri A Hicks, J Thomas Cross, Nick Fitterman, Johanna Lewis und 8 weitere

Annals of Internal Medicine · 2025-03 · 178 (3) · 426-433

DOI: 10.7326/annals-24-01052 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annals of Internal Medicine, 2025-03. Verfasst von Amir Qaseem und 19 weiteren Autor:innen. Beteiligte Einrichtung: American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E., C.S.H.). Hauptthemen laut MEDLINE: Ambulatory Care, Migraine Disorders. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DESCRIPTION: The American College of Physicians (ACP) developed this clinical guideline for clinicians caring for adults with episodic migraine headache (defined as 1 to 14 headache days per month) in outpatient settings. METHODS: ACP based these recommendations on systematic reviews of the comparative benefits and harms of pharmacologic treatments to prevent episodic migraine, patients' values and preferences, and economic evidence. ACP evaluated the comparative effectiveness of the following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan and telmisartan), antiseizure medications (valproate and topiramate), β-blockers (metoprolol and propranolol), calcitonin gene-related peptide (CGRP) antagonist-gepants (atogepant or rimegepant), CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, or galcanezumab), selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors (fluoxetine and venlafaxine), and a tricyclic antidepressant (amitriptyline). ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency department visits, migraine-related disability, quality of life and physical functioning, and discontinuations due to adverse events. In addition, adverse events were captured through U.S. Food and Drug Administration medication labels and eligible studies. RECOMMENDATIONS: In this guideline, ACP makes recommendations for clinicians to initiate monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting as well as alternative approaches if initial treatments are not tolerated or result in an inadequate response. All 3 ACP recommendations have conditional strength and low-certainty evidence. Clinical considerations provide additional context for physicians and other clinicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ambulatory CareMigraine DisordersHumansAngiotensin-Converting Enzyme InhibitorsAnticonvulsantsCalcitonin Gene-Related Peptide Receptor Antagonists

Substanzen

Angiotensin-Converting Enzyme InhibitorsAnticonvulsantsCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E., C.S.H.).
  • Oregon Health & Science University, Portland, Oregon (T.G.C.).
  • Minneapolis VA Health Care System and the University of Minnesota Schools of Medicine and Public Health, Minneapolis, Minnesota (T.J.W.).
  • University of California, San Francisco, San Francisco, California (J.A.T.).
  • David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (C.J.C.).

ORCID-Profile: Amir Qaseem, Itziar Etxeandia-Ikobaltzeta, Jeffrey A Tice

Zitieren

APA

Qaseem, A., Cooney, T. G., Etxeandia-Ikobaltzeta, I., Wilt, T. J., Harrod, C. S., Tice, J. A., Crandall, C. J., Clinical Guidelines Committee of the American College of Physicians, Hicks, L. A., Cross, J. T., Fitterman, N., Lewis, J., Linsky, A. M., Maroto, M., Miller, M. C., Obley, A. J., Owens, D. K., Shekelle, P. G., Shamliyan, T., & Yost, J. (2025). Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine, 178(3), 426-433. https://doi.org/10.7326/annals-24-01052

Vancouver

Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Tice JA, et al. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2025;178(3):426-433. doi:10.7326/annals-24-01052

BibTeX
@article{Qaseem2025,
  author = {Qaseem, Amir and Cooney, Thomas G and Etxeandia-Ikobaltzeta, Itziar and Wilt, Timothy J and Harrod, Curtis S and Tice, Jeffrey A and Crandall, Carolyn J and Clinical Guidelines Committee of the American College of Physicians, Clinical Guidelines Committee of the American College of Physicians and Hicks, Lauri A and Cross, J Thomas and Fitterman, Nick and Lewis, Johanna and Linsky, Amy M and Maroto, Michael and Miller, Matthew C and Obley, Adam J and Owens, Douglas K and Shekelle, Paul G and Shamliyan, Tatyana and Yost, Jennifer},
  title = {Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {3},
  pages = {426--433},
  doi = {10.7326/annals-24-01052}
}
Kostenlos starten →